天准科技：10月24日召开董事会会议

Group 1 - The company Tianzhun Technology announced on October 24 that its fourth board meeting was held, where it reviewed the proposal to cancel part of the restricted stock incentive plan from 2022 [1] - The meeting was conducted in a hybrid format, combining in-person attendance with remote voting [1] Group 2 - The Chinese innovative drug sector has generated $80 billion in overseas licensing deals this year [1] - A conversation with Lu Gang, a partner at Chuangdong Investment, highlighted the hot secondary market in biomedicine, while the primary market is facing challenges in fundraising [1]